Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study

Atherosclerosis

Volumn 228, Issue 1, 2013, Pages 230-236

  Robins, Sander J ^a   Lyass, Asya ^b   Brocia, Robert W ^c   Massaro, Joseph M ^d   Vasan, Ramachandran S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Boston University   (United States)

^c Roar Biomedical Inc   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cholesteryl ester transfer protein; High density lipoproteins; Phospholipid transfer protein

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; FEMALE; FLUOROMETRY; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MASSACHUSETTS; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PHOSPHOLIPIDS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX DISTRIBUTION;

EID: 84876785357     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.01.046     Document Type: Article

References (31)

1. Clark R.W., Sutfin T.A., Ruggeri R.B., et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004, 24:490-497.
2. Settasatian N., Duong M.N., Curtiss L.K., et al. The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem 2001, 276:26898-26905.
3. Jiang X., Francone O.L., Bruce C., et al. Increased prebeta-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J Clin Invest 1996, 98:2373-2380.
4. Vasan R.S., Pencina M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.
5. Ritsch A., Scharnagl H., Eller P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 2010, 121:366-374.
6. Khera A.V., Wolfe M.L., Cannon C.P., Qin J., Rader D.J. On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy - thrombolysis in myocardial infarction 22 [PROVE-IT-TIMI 22] Study). Am J Cardiol 2010, 106:451-456.
7. Nissen S.E., Tardif J.-C., Nicholls S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304-1316.
8. Schwartz G.G., Olsson A.G., Abt M., et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012, 367:2089-2099.
9. Schlitt A., Blankenberg S., Bickel C., et al. PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. J Lipid Res 2009, 50:723-729.
10. Schlitt A., Bickel C., Thumma P., et al. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23:1857-1862.
11. Vergeer M., Boekholdt M., Sandhu M.S., et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010, 122:470-477.
12. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., Castelli W.P. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 1979, 110:281-290.
13. Selvin S. Statistical analysis of epidemiologic data 1996, Oxford Univ. Press, New York, NY, p. 208. 3rd ed.
14. Pencina M.J., D'Agostino R.B. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004, 23:2109-2123.
15. Pencina M.J., D'Agostino R.B., Steyerbergd E.W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21.
16. Cannon C.P., Shah S., Dansky H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010, 363:2406-2415.
17. Boekholdt S.M., Kuivenhoven J.-A., Wareham N.J., et al. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women. Circulation 2004, 110:1418-1423.
18. Borggreve S.E., Hillege H.L., Dallinga-Thie G.M., et al. High plasma cholesteryl ester transfer protein may favour reduced incidence of cardiovascular events in men with low triglycerides. Eur Heart J 2007, 28:1012-1018.
19. Kappelle P.J.W.H., Perton F., Hillege H.L., Dallinga-Thie G.M., Dullaart R.P.F. High plasma cholesteryl ester transfer but not mass predicts incident cardiovascular disease: a nested case-control study. Atherosclerosis 2011, 217:249-252.
20. Zeller M., Masson D., Farnier M., et al. High serum cholesteryl ester transfer rates and small high-density lipoproteins are associated with young age in patients with acute myocardial infarction. J Am Coll Cardiol 2007, 50:1948-1955.
21. Cavusoglu E., Marmur J.D., Chhabra S., Chopra V., Eng C., Jiang X.-C. Relation of baseline plasma phospholipid transfer protein (PLTP) activity to left ventricular systolic dysfunction in patients referred for coronary angiography. Atherosclerosis 2009, 207:261-265.
22. deVries R., Dallinga-Thie G.M., Smit A.J., Wolffenbuttel B.H.R., van Tol A., Dullaart R.P.F. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006, 49:398-404.
23. Schgoer W., Mueller T., Jauhiainen M., et al. Low phospholipid transfer protein is a risk factor for peripheral atherosclerosis. Atherosclerosis 2008, 196:219-226.
24. Jiang X.-C., Bruce C., Mar J., et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J Clin Invest 1999, 103:907-914.
25. van Haperen R., van Tol A., Vermeulen P., et al. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arterioscler Thromb Vasc Biol 2000, 20:1082-1088.
26. Jaari S., van Dijk K.W., Olkkonen V.M., et al. Dynamic changes in mouse lipoproteins induced by transiently expressed human phospholipid transfer protein (PLTP): importance of PLTP in preβ-HDL generation. Comp Biochem Physiol Part B 2001, 128:781-792.
27. Jiang X.-C., Qin S., Qiao C., et al. Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat Med 2001, 7:847-852.
28. Schlitt A., Liu J., Yan D., Mondragon-Escorpizo M., Norin A.J., Jiang X.C. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 2005, 1733:187-191.
29. Cheung M.C., Brown B.G., Larsen E.K.M., Frutkin A.D., O'Brien K.D., Albers J.J. Phospholipid transfer protein activity is associated with inflammatory markers in patients with cardiovascular disease. Biochim Biophys Acta 2006, 1762:131-137.
30. Schwartz C.C., VandenBroek J.M., Cooper P.S. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res 2004, 45:1594-1607.
31. Harada L.M., Amigo L., Cazita P.M., et al. CETP expression enhances liver HDL-cholesteryl ester uptake but does not alter VLDL and biliary lipid secretion. Atherosclerosis 2007, 191:313-318.